Related Experiment Video

Updated: Mar 30, 2026

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.8K

Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection

Vinay Sundaram1, Kris V Kowdley

  • 1a Department of Medicine and Comprehensive Transplant Center , Cedars-Sinai Medical Center , Los Angeles , CA , USA.

Expert Review of Gastroenterology & Hepatology
|November 13, 2015
PubMed

Insights

New direct-acting antiviral therapies, including sofosbuvir and daclatasvir, offer improved treatment for chronic hepatitis C virus (HCV) genotype 3 infections, a previously difficult-to-treat condition.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C virus (HCV) infection is a leading cause of liver disease mortality globally.
  • Traditional therapies like pegylated interferon and ribavirin showed limited efficacy, particularly for HCV genotype 1 and 3.
  • Direct-acting antivirals (DAAs) have revolutionized HCV treatment, significantly improving cure rates, especially for genotype 1.

Purpose of the Study:

  • To evaluate the efficacy of novel direct-acting antiviral (DAA) combinations for treating chronic hepatitis C virus (HCV) genotype 3.
  • To address the challenge of treating HCV genotype 3, which has shown lower response rates to older therapies.

Main Methods:

  • Utilized sofosbuvir, a potent pan-genotypic nucleotide analogue inhibiting HCV NS5B polymerase.
  • Incorporated daclatasvir, a pan-genotypic inhibitor of the HCV NS5A replication complex.
  • Investigated the combination therapy for HCV genotype 3 treatment.

Main Results:

  • Sofosbuvir demonstrates potent inhibition of HCV NS5B polymerase.
  • Daclatasvir targets the HCV NS5A replication complex.
  • The combination of sofosbuvir and daclatasvir shows promise for treating HCV genotype 3.

Conclusions:

  • The combination of sofosbuvir and daclatasvir represents a significant advancement in treating chronic hepatitis C virus genotype 3.
  • This novel DAA therapy offers a powerful new option for patients with HCV genotype 3, potentially overcoming previous treatment challenges.

Keywords:
Direct-acting antiviralgenotype 1pegylated interferonribavirin

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
Reverse Genetics to Engineer Positive-Sense RNA Virus Variants15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

2.0K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.6K
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
37
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
749
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
748
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
627